Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax for high-risk stage A CLL (PREVENE)
NCT03766763Phase 2Active, not recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- May 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by French Innovative Leukemia Organisation. Started May 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03766763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766763.